Multi-stakeholder collaborations & biomarker development and implementation
暂无分享,去创建一个
[1] J. Woodcock. Assessing the Clinical Utility of Diagnostics Used in Drug Therapy , 2010, Clinical pharmacology and therapeutics.
[2] B. Evans. Establishing Clinical Utility of Pharmacogenetic Tests in the Post‐FDAAA Era , 2010, Clinical pharmacology and therapeutics.
[3] F. Frueh,et al. Evidence of Clinical Utility: An Unmet Need in Molecular Diagnostics for Patients with Cancer , 2014, Clinical Cancer Research.
[4] Richard Pazdur,et al. Pathological complete response and accelerated drug approval in early breast cancer. , 2012, The New England journal of medicine.
[5] D. Berry,et al. I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.
[6] A Model for Accelerating Identification and Regulatory Approval of Effective Investigational Agents , 2012 .
[7] Alisa Opar. Bridging the drug—diagnostic divide , 2011, Nature Reviews Drug Discovery.
[8] Janet Woodcock,et al. Accelerating identification and regulatory approval of investigational cancer drugs. , 2011, JAMA.
[9] E. Berndt,et al. Economic challenges and possible policy actions to advance stratified medicine. , 2012, Personalized medicine.
[10] C. Sigman,et al. Cancer biomarkers: selecting the right drug for the right patient , 2012, Nature Reviews Drug Discovery.
[11] A. Chinnaiyan,et al. Systematic, evidence-based discovery of biomarkers at the NCI , 2012, Clinical & Experimental Metastasis.
[12] Steven Gutman,et al. Opinion: The US Food and Drug Administration perspective on cancer biomarker development , 2006, Nature Reviews Cancer.
[13] G. Rasi,et al. Cancer Drug Development and the Evolving Regulatory Framework for Companion Diagnostics in the European Union , 2014, Clinical Cancer Research.
[14] Krishna Prasad,et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium , 2010, Nature Biotechnology.
[15] Master Protocol for squamous cell lung cancer readies for launch , 2014, Nature Biotechnology.
[16] D Amakye,et al. A Prototypical Process for Creating Evidentiary Standards for Biomarkers and Diagnostics , 2008, Clinical pharmacology and therapeutics.
[17] F. Frueh,et al. Biomarker qualification pilot process at the US Food and Drug Administration , 2007, The AAPS Journal.
[18] Nola Hylton,et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] E. Mansfield,et al. FDA Perspective on Companion Diagnostics: An Evolving Paradigm , 2014, Clinical Cancer Research.
[20] Frank D Sistare,et al. Research at the interface of industry, academia and regulatory science , 2010, Nature Biotechnology.
[21] Efthymios Manolis,et al. New pathway for qualification of novel methodologies in the European medicines agency , 2011, Proteomics. Clinical applications.
[22] F. Goodsaid,et al. Translational Medicine and the Value of Biomarker Qualification , 2010, Science Translational Medicine.
[23] A. Szarfman,et al. Qualification of cardiac troponins for nonclinical use: a regulatory perspective. , 2013, Regulatory toxicology and pharmacology : RTP.
[24] C. Compton,et al. Public-private partnerships as driving forces in the quest for innovative medicines , 2013, Clinical and Translational Medicine.
[25] Jiri Aubrecht,et al. Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact , 2010, Nature Reviews Drug Discovery.
[26] James H. Doroshow,et al. AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development , 2010, Clinical Cancer Research.
[27] Staffan Jacobsson,et al. Innovation systems: analytical and methodological issues , 2002 .
[28] S. McCune,et al. The Critical Path Initiative: Leveraging Collaborations to Enhance Regulatory Science , 2012, Clinical pharmacology and therapeutics.
[29] Kristen Anton,et al. Bioinformatics: biomarkers of early detection. , 2010, Cancer biomarkers : section A of Disease markers.
[30] George Poste,et al. Biospecimens, biomarkers, and burgeoning data: the imperative for more rigorous research standards. , 2012, Trends in molecular medicine.
[31] R. Hockett,et al. Regulation of Laboratory‐Developed Tests: The Case for Utilizing Professional Associations , 2010, Clinical pharmacology and therapeutics.
[32] Federico M Goodsaid,et al. Strategic paths for biomarker qualification. , 2008, Toxicology.
[33] J. Bonventre,et al. Biomarkers : in medicine, drug discovery, and environmental health , 2010 .
[34] Federico Goodsaid,et al. Evolution of biomarker qualification at the health authorities , 2010, Nature Biotechnology.
[35] Sujoy Ghosh,et al. The Biomarkers Consortium: Practice and Pitfalls of Open‐Source Precompetitive Collaboration , 2010, Clinical pharmacology and therapeutics.
[36] Leslie M. Shaw,et al. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium , 2013, Alzheimer's & Dementia.
[37] Charles C. Persinger,et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.
[38] S. Amur,et al. The Experience with Voluntary Genomic Data Submissions at the FDA and a Vision for the Future of the Voluntary Data Submission Program , 2007, Clinical pharmacology and therapeutics.
[39] Gene A Pennello,et al. Analytical and clinical evaluation of biomarkers assays: When are biomarkers ready for prime time? , 2013, Clinical trials.
[40] Janet Woodcock,et al. The FDA critical path initiative and its influence on new drug development. , 2008, Annual review of medicine.
[41] E. Gillanders,et al. Translational Research in Cancer Genetics: The Road Less Traveled , 2009, Public Health Genomics.
[42] Asher Mullard,et al. 2013 FDA drug approvals , 2014, Nature Reviews Drug Discovery.
[43] Malorye Allison. Biomarker-led adaptive trial blazes a trail in breast cancer , 2010, Nature Biotechnology.
[44] Greg Miller,et al. Alzheimer's biomarker initiative hits its stride. , 2009, Science.
[45] Jiri Aubrecht,et al. The current status of biomarkers for predicting toxicity , 2013, Expert opinion on drug metabolism & toxicology.
[46] K. Coombes,et al. What information should be required to support clinical "omics" publications? , 2011, Clinical chemistry.
[47] J. Wagner,et al. Biomarkers and Surrogate End Points for Fit‐for‐Purpose Development and Regulatory Evaluation of New Drugs , 2007, Clinical pharmacology and therapeutics.
[48] Bradley L. Smith,et al. Development of Targeted Agents and Companion Diagnostics , 2012 .
[49] Evolving Global Regulatory Science Through the Voluntary Submission of Data , 2014, Therapeutic innovation & regulatory science.
[50] E. Berndt,et al. Uncertain prognosis for high-quality diagnostics: clinical challenges, economic barriers and needed reforms. , 2013, Pharmacogenomics.
[51] F. Frueh,et al. REVIEWTHEME : GENERAL Integration and use of biomarkers in drug development , regulation and clinical practice : a US regulatory perspective , 2008 .
[52] F. Frueh,et al. Experience with voluntary and required genomic data submissions to the FDA: summary report from track 1 of the third FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop , 2006, The Pharmacogenomics Journal.
[53] I. Zineh,et al. Pharmacogenetics in medicine: barriers, critical factors and a framework for dialogue. , 2009, Personalized medicine.
[54] D. DeMets,et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.
[55] Competitors try collaboration to speed drug development. , 2010, Journal of the National Cancer Institute.
[56] Sudhir Srivastava,et al. The early detection research network: 10-year outlook. , 2013, Clinical chemistry.
[57] H. Etzkowitz,et al. Triple Helix Systems: An Analytical Framework for Innovation Policy and Practice in the Knowledge Society , 2013 .
[58] Joel Cutcher-Gershenfeld,et al. Precompetitive consortia in biomedicine—how are we doing? , 2013, Nature Biotechnology.
[59] Ohid Yaqub,et al. Public-private collaborations and partnerships in stratified medicine: making sense of new interactions. , 2012, New biotechnology.
[60] Christine M. Micheel,et al. Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease , 2010 .
[61] Viswanath Devanarayan,et al. Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement , 2006, Pharmaceutical Research.
[62] C. Jack,et al. Alzheimer's Disease Neuroimaging Initiative , 2008 .
[63] Rajiv Mahajan,et al. Food and drug administration’s critical path initiative and innovations in drug development paradigm: Challenges, progress, and controversies , 2010, Journal of pharmacy & bioallied sciences.
[64] S. Ghosh,et al. Utility of Adiponectin as a Biomarker Predictive of Glycemic Efficacy Is Demonstrated by Collaborative Pooling of Data From Clinical Trials Conducted by Multiple Sponsors , 2009, Clinical pharmacology and therapeutics.
[65] K. Romero,et al. The Coalition Against Major Diseases: Developing Tools for an Integrated Drug Development Process for Alzheimer's and Parkinson's Diseases , 2009, Clinical pharmacology and therapeutics.
[66] Z. Khachaturian. Perspective on the Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans , 2010, Alzheimer's & Dementia.
[67] Frank D Sistare,et al. Towards consensus practices to qualify safety biomarkers for use in early drug development , 2010, Nature Biotechnology.
[68] S. Teutsch,et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group , 2009, Genetics in Medicine.
[69] E. Drucker,et al. Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine , 2013, EPMA Journal.
[70] Marc S. Williams,et al. The EGAPP initiative: lessons learned , 2013, Genetics in Medicine.
[71] L. Lesko,et al. Paving the Critical Path: How can Clinical Pharmacology Help Achieve the Vision? , 2007, Clinical pharmacology and therapeutics.
[72] M. Goldman,et al. The Innovative Medicines Initiative: A European Response to the Innovation Challenge , 2012, Clinical pharmacology and therapeutics.
[73] M. Day,et al. Translational medicine--a paradigm shift in modern drug discovery and development: the role of biomarkers. , 2009, Advances in experimental medicine and biology.
[74] I. Zineh,et al. Qualifying biomarkers for use in drug development: a US Food and Drug Administration overview. , 2011, Expert opinion on medical diagnostics.
[75] F. Pammolli,et al. The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.
[76] Asher Mullard,et al. Multicompany trials adapt to disciplines beyond cancer , 2014, Nature Medicine.
[77] Eslie Dennis,et al. Opportunities and Challenges of Safety Biomarker Qualification: Perspectives from the Predictive Safety Testing Consortium , 2013 .
[78] Adrian Burton,et al. Big science for a big problem: ADNI enters its second phase , 2011, The Lancet Neurology.
[79] B. Quinn. Payers and the Assessment of Clinical Utility for Companion Diagnostics , 2010, Clinical pharmacology and therapeutics.
[80] D. Carbone,et al. Leveling the Playing Field: Bringing Development of Biomarkers and Molecular Diagnostics up to the Standards for Drug Development , 2012, Clinical Cancer Research.
[81] P. Aisen. Q & A: The Alzheimer's disease neuroimaging initiative , 2011, BMC medicine.
[82] L. Lesko,et al. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. , 2001, Annual review of pharmacology and toxicology.
[83] Federico Goodsaid,et al. Process map proposal for the validation of genomic biomarkers. , 2006, Pharmacogenomics.
[84] M S Pepe,et al. Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.
[85] J. Wagner. Strategic approach to fit-for-purpose biomarkers in drug development. , 2008, Annual review of pharmacology and toxicology.
[86] B. Conley,et al. Bridging the Gap: Moving Predictive and Prognostic Assays from Research to Clinical Use , 2012, Clinical Cancer Research.
[87] Impact of discrepant results from clinical laboratories on patients and pharmaceutical trials: evidence from proficiency testing results. , 2009, Biomarkers in medicine.
[88] Krishna Kodukula,et al. Biomarkers in pharmacology and drug discovery. , 2014, Biochemical pharmacology.
[89] Andrea C. Rinaldi,et al. Teaming up for biomarker future , 2011, EMBO reports.
[90] A. Senderowicz,et al. Similarities and Differences in the Oncology Drug Approval Process between FDA and European Union with Emphasis on In Vitro Companion Diagnostics , 2014, Clinical Cancer Research.
[91] J. Bozell. Breaking the vicious cycle. , 2007, Mental health today.
[92] H. Zwierzina,et al. Biomarkers in drug development. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[93] Weida Tong,et al. FDA-approved drug labeling for the study of drug-induced liver injury. , 2011, Drug discovery today.
[94] Ronald L Weiss,et al. The long and winding regulatory road for laboratory-developed tests. , 2012, American journal of clinical pathology.
[95] Abdel-Baset Halim,et al. Biomarkers in Drug Development: A Useful Tool but Discrepant Results May Have a Major Impact , 2011 .
[96] P. Wagner,et al. New paradigms in translational science research in cancer biomarkers. , 2012, Translational research : the journal of laboratory and clinical medicine.
[97] F. Dieterle,et al. Promises of Biomarkers in Drug Development – A Reality Check , 2007, Chemical biology & drug design.